Estrella Immunopharma Reports Director/Officer Changes
Ticker: ESLAW · Form: 8-K · Filed: Sep 26, 2025 · CIK: 1844417
Sentiment: neutral
Topics: management-change, board-election, officer-appointment, compensation
Related Tickers: ESLA
TL;DR
Estrella Immunopharma (ESLA) filed an 8-K detailing director and officer changes, plus new compensation plans.
AI Summary
Estrella Immunopharma, Inc. filed an 8-K on September 26, 2025, reporting events as of September 22, 2025. The filing indicates a departure of directors or certain officers, the election of new directors, and the appointment of certain officers, along with details on compensatory arrangements for these officers. The company, formerly known as TradeUP Acquisition Corp., is in the biological products sector.
Why It Matters
Changes in a company's board and executive team can signal shifts in strategy, operational focus, or governance, potentially impacting future performance and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directorship and officer roles, especially when accompanied by new compensatory arrangements, can introduce uncertainty about future strategy and leadership stability.
Key Players & Entities
- Estrella Immunopharma, Inc. (company) — Registrant
- TradeUP Acquisition Corp. (company) — Former company name
- September 22, 2025 (date) — Earliest event reported date
- September 26, 2025 (date) — Filing date
FAQ
What specific changes occurred regarding directors and officers at Estrella Immunopharma?
The 8-K filing indicates the departure of directors or certain officers, the election of new directors, and the appointment of certain officers.
When were the events reported in this 8-K filing dated?
The earliest event reported in the filing is dated September 22, 2025.
What is the filing date of this 8-K for Estrella Immunopharma?
The 8-K was filed on September 26, 2025.
What was Estrella Immunopharma's former company name?
Estrella Immunopharma, Inc. was formerly known as TradeUP Acquisition Corp.
What information is provided regarding compensatory arrangements?
The filing mentions compensatory arrangements of certain officers in relation to the changes in directorship and officer appointments.
Filing Stats: 557 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2025-09-26 17:25:27
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ESLA The Nasdaq Stock Mar
- $11.50 — of Common Stock at an exercise price of $11.50 ESLAW The Nasdaq Stock Market LLC
Filing Documents
- ea0259031-8k_estrella.htm (8-K) — 30KB
- 0001213900-25-092471.txt ( ) — 238KB
- esla-20250922.xsd (EX-101.SCH) — 4KB
- esla-20250922_def.xml (EX-101.DEF) — 26KB
- esla-20250922_lab.xml (EX-101.LAB) — 36KB
- esla-20250922_pre.xml (EX-101.PRE) — 25KB
- ea0259031-8k_estrella_htm.xml (XML) — 6KB
02 Departure of Directors or Certain
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 22, 2025, the Board of Directors (the "Board") of Estrella Immunopharma, Inc. (the "Company") appointed Jia Dengyao to serve as a member of the Board, effective immediately. As of the date of this Current Report on Form 8-K, Mr. Jia has not been appointed and is not expected to be appointed to any committees of the Board. In connection with the appointment of Mr. Jia, the Company entered into an indemnification agreement with Mr. Jia on substantially similar terms as the indemnification agreements the Company has previously entered into with its other non-employee directors. This indemnification agreement requires the Company to indemnify Mr. Jia for certain reasonable expenses, including attorneys' fees and retainers, court costs, and witness and expert costs, incurred by Mr. Jia in any action or proceeding, and any appeal thereof, arising out of his service as a director of the Company or any other company to which Mr. Jia provides services at the request of the Company. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Estrella Immunopharma, Inc. By: /s/ Cheng Liu Name: Cheng Liu Title: Chief Executive Officer Date: September 26, 2025 2